Latest
By Stephen Nellis / Friday, January 17th, 2014 / Technology, Top Stories / Comments Off on Round 2: Atara raises $13.5M as T.O. biotech boom takes hold
Thousand Oaks-based Atara Biotherapeutics has brought on more investors to its second financing round, bringing the total raised to $52 million.
Read More →
Latest
By Stephen Nellis / Friday, December 20th, 2013 / East Ventura County, Technology, Top Stories, Tri-County Economy / Comments Off on Atara raises $38.5M for dialysis, cancer drugs
Atara Biotherapeutics, a Thousand Oaks firm that emerged last year with major Silicon Valley backers and licenses to develop six Amgen assets, has raised $38.5 million to pursue treatments for dialysis complications and ovarian cancer.
Read More →
Latest
By Tom Bronzini / Friday, December 20th, 2013 / Columns, Wine & Viticulture / Comments Off on Showcasing some wines seldom heard of on the grapevine
It’s a lot easier to drink than pronounce the names of the lesser-known Italian varietal wines poured at the Sunland Vintage Winery tasting room in Thousand Oaks.
Read More →
Latest
By Staff Report / Tuesday, December 17th, 2013 / Central Coast Health Watch, Technology, Top Stories / Comments Off on Amgen spinout Atara raises $38.5 million
Atara Biotherapeutics, a Thousand Oaks firm that emerged last year with major Silicon Valley backers and licenses to develop six Amgen assets, has raised $38.5 million to pursue treatments for dialysis complications and ovarian cancer.
Read More →
Latest
By Guest commentary / Friday, November 29th, 2013 / Op/Eds, Opinion / Comments Off on Op/ed: Maintaining the talent flow — How to retain your best workers
The ever-increasing focus on the effective management of people, especially those who are key to an organization’s success, is one of the most important developments in management in the past 15 years. Starting with a seminal McKinsey study in 1998 and the authors’ 2001 book “The War for Talent,” the field of talent management has gained much respect and attention from scholars and practitioners across industries and national boundaries.
Read More →
Latest
By Stephen Nellis / Friday, November 15th, 2013 / Central Coast Health Watch, Technology, Top Stories / Comments Off on Thousand Oaks cancer drug firm raises $9M
Thousand Oaks-based ImmunGene, a cancer treatment firm led by a former Amgen scientist, has raised $9 million from Ally Bridge Group, an investment group with ties to Hong Kong.
ImmunGene’s so-called antibody-cytokine fusion technology could help improve the cancer-cell targeting in therapies. President and CEO Sanjay D. Khare was formerly the scientific director at Amgen, the biotech giant. Prior to the funding, ImmunGene had received several hundred thousand dollars in federal research grants.
Antibody technologies hold promise for creating cancer treatments that do less damage to healthy cells. Molecules are crafted to mimic the body’s own immune system and bind to specific defects in cancer cells.
Read More →
